366 related articles for article (PubMed ID: 27113227)
21. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
Perraudin C; Bourdin A; Vicino A; Kuntzer T; Bugnon O; Berger J
PLoS One; 2020; 15(11):e0242630. PubMed ID: 33237959
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
23. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.
Sun D; Heimall JR; Greenhawt MJ; Bunin NJ; Shaker MS; Romberg N
JAMA Pediatr; 2022 Feb; 176(2):176-184. PubMed ID: 34779842
[TBL] [Abstract][Full Text] [Related]
24. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
25. Current treatments for CIDP.
Ropper AH
Neurology; 2003 Apr; 60(8 Suppl 3):S16-22. PubMed ID: 12707418
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
[TBL] [Abstract][Full Text] [Related]
28. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
Tracy JA; Dyck PJ
Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model.
Paltiel AD; Fuhlbrigge AL; Kitch BT; Liljas B; Weiss ST; Neumann PJ; Kuntz KM
J Allergy Clin Immunol; 2001 Jul; 108(1):39-46. PubMed ID: 11447380
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
Permsuwan U; Dilokthornsakul P; Thavorn K; Saokaew S; Chaiyakunapruk N
J Med Econ; 2017 Feb; 20(2):171-181. PubMed ID: 27645706
[TBL] [Abstract][Full Text] [Related]
31. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
Adrichem ME; Eftimov F; van Schaik IN
J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
[TBL] [Abstract][Full Text] [Related]
32. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
[TBL] [Abstract][Full Text] [Related]
33. Childhood acute and chronic immune-mediated polyradiculoneuropathies.
Rabie M; Nevo Y
Eur J Paediatr Neurol; 2009 May; 13(3):209-18. PubMed ID: 18585069
[TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
35. Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; van Doorn PA; Bengrine T; van Rijs W; Baas F; Nagelkerke SQ; Kuijpers TW; Fokkink WR; Bunschoten C; Broers MC; Willemsen SP; Jacobs BC; Huizinga R
Eur J Neurol; 2021 May; 28(5):1677-1683. PubMed ID: 33460483
[TBL] [Abstract][Full Text] [Related]
36. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
[TBL] [Abstract][Full Text] [Related]
37. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
38. Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada.
Herring W; Pearson I; Purser M; Nakhaipour HR; Haiderali A; Wolowacz S; Jayasundara K
Pharmacoeconomics; 2016 Jan; 34(1):77-90. PubMed ID: 26518293
[TBL] [Abstract][Full Text] [Related]
39. [Treatment options for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)].
Kuntzer T
Rev Neurol (Paris); 2006 Apr; 162(4):539-43. PubMed ID: 16585918
[TBL] [Abstract][Full Text] [Related]
40. Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany.
Mengel D; Fraune L; Sommer N; Stettner M; Reese JP; Dams J; Glynn RJ; Balzer-Geldsetzer M; Dodel R; Tackenberg B
Muscle Nerve; 2018 Nov; 58(5):681-687. PubMed ID: 30073683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
